Wasp Venom Biochemical Components and Their Potential in Biological Applications and Nanotechnological Interventions

• Main Authors: Aida Abd El-Wahed, Nermeen Yosri, Hanem H. Sakr, Ming Du, Ahmed F. M. Algethami, Chao Zhao, Ahmed H. Abdelazeem, Haroon Elrasheid Tahir, Saad H. D. Masry, Mohamed M. Abdel-Daim, Syed Ghulam Musharraf, Islam El-Garawani, Guoyin Kai, Shaden A. M. Khalifa, Hesham R. El-Seedi
• Format: Article
• Language: English
• Published: MDPI AG 2021-03-01
• Series: Toxins
• Subjects: wasp’s venom; biomedical properties; bioactive compounds; nanotechnology applications; allergy
• Online Access: https://www.mdpi.com/2072-6651/13/3/206

Wasps, members of the order Hymenoptera, are distributed in different parts of the world, including Brazil, Thailand, Japan, Korea, and Argentina. The lifestyles of the wasps are solitary and social. Social wasps use venom as a defensive measure to protect their colonies, whereas solitary wasps use their venom to capture prey. Chemically, wasp venom possesses a wide variety of enzymes, proteins, peptides, volatile compounds, and bioactive constituents, which include phospholipase A2, antigen 5, mastoparan, and decoralin. The bioactive constituents have anticancer, antimicrobial, and anti-inflammatory effects. However, the limited quantities of wasp venom and the scarcity of advanced strategies for the synthesis of wasp venom’s bioactive compounds remain a challenge facing the effective usage of wasp venom. Solid-phase peptide synthesis is currently used to prepare wasp venom peptides and their analogs such as mastoparan, anoplin, decoralin, polybia-CP, and polydim-I. The goal of the current review is to highlight the medicinal value of the wasp venom compounds, as well as limitations and possibilities. Wasp venom could be a potential and novel natural source to develop innovative pharmaceuticals and new agents for drug discovery.